All In Biotech

Drug Trial Radar · NCT02437318

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment

Last checked: Nov 20, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 572 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

572

Actual

Start

Jul 23, 2015

Primary completion

Jun 12, 2018

Study completion Jun 9, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine whether treatment with alpelisib plus fulvestrant prolonged progression-free survival (PFS) compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 (HER2)-negative advanced breast cancer, who received prior treatment with an aromatase Inhibitor (AI) either as (neo)adjuvant or for advanced disease.

Conditions

  • Breast Cancer

Interventions

  • FulvestrantDrug

    500 mg of fulvestrant administered via intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle

  • AlpelisibDrug

    300 mg of alpelisib tablets for oral use administered once daily

  • PlaceboDrug

    300 mg of placebo tablets for oral use administered once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant CohortTime frame: Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months

Locations

197 sites in 31 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Mayo Clinic Arizona

    Scottsdale, Arizona

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • City of Hope National Medical Center

    Duarte, California

  • Scripps Green Hospital

    La Jolla, California

  • Kaiser Permanent Southern Californi

    San Diego, California

  • UCSF

    San Francisco, California

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Florida Cancer Specialists-North

    St. Petersburg, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • NorthShore University Health System

    Evanston, Illinois

  • Edward Cancer Center

    Naperville, Illinois

  • Fort Wayne Medical Oncology Hematology Inc

    Fort Wayne, Indiana

  • St Francis Health Comprehensive Cancer Center

    Topeka, Kansas

  • Mercy Medical Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Lahey Clinic

    Burlington, Massachusetts

  • Detroit Clinical Research Center

    Owosso, Michigan

  • St Lukes Cancer Institute

    Kansas City, Missouri

  • St Vincent Frontier Cancer Center

    Billings, Montana

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • University Hospitals of Cleveland Seidman Cancer Center

    Cleveland, Ohio

  • Good Samaritan Regional Medical Center

    Corvallis, Oregon

  • Lancaster General Hospital

    Lancaster, Pennsylvania

  • Prisma Health Upstate

    Greenville, South Carolina

  • Avera Cancer

    Sioux Falls, South Dakota

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Texas Oncology PA Dallas Presbyterian Hospital

    Dallas, Texas

  • El Paso Texas Oncology

    El Paso, Texas

  • Mays Cancer Ctr Uthsa Mdacc

    San Antonio, Texas

  • Texas Oncology Northeast Texas

    Tyler, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Wenatchee Valley Medical Center

    Wenatchee, Washington

  • Novartis Investigative Site

    La Rioja, Argentina

  • Novartis Investigative Site

    Berazategui, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Rio Negro, Viedma, Argentina

  • Novartis Investigative Site

    Wahroonga, New South Wales, Australia

  • Novartis Investigative Site

    Wooloongabba, Queensland, Australia

Showing 40 of 197 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.